liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis
Univ Toronto, Canada; Univ Hlth Network, Canada.
Univ Toronto, Canada; Univ Hlth Network, Canada.
Univ Toronto, Canada; Univ Hlth Network, Canada.
Univ Hlth Network, Canada.
Show others and affiliations
2018 (English)In: Molecular Cell, ISSN 1097-2765, E-ISSN 1097-4164, Vol. 72, no 5, p. 836-+Article in journal (Refereed) Published
Abstract [en]

Transforming members of the MYC family (MYC, MYCL1, and MYCN) encode transcription factors containing six highly conserved regions, termed MYC homology boxes (MBs). By conducting proteomic profiling of the MB interactomes, we demonstrate that half of the MYC interactors require one or more MBs for binding. Comprehensive phenotypic analyses reveal that two MBs, MBO and MBII, are universally required for transformation. MBII mediates interactions with acetyltransferase-containing complexes, enabling histone acetylation, and is essential for MYC-dependent tumor initiation. By contrast, MBO mediates interactions with transcription elongation factors via direct binding to the general transcription factor TFIIF. MBO is dispensable for tumor initiation but is a major accelerator of tumor growth. Notably, the full transforming activity of MYC can be restored by co-expression of the non-transforming MBO and MBII deletion proteins, indicating that these two regions confer separate molecular functions, both of which are required for oncogenic MYC activity.

Place, publisher, year, edition, pages
CELL PRESS , 2018. Vol. 72, no 5, p. 836-+
National Category
Biochemistry and Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-153678DOI: 10.1016/j.molcel.2018.09.031ISI: 000452547600006PubMedID: 30415952OAI: oai:DiVA.org:liu-153678DiVA, id: diva2:1276234
Note

Funding Agencies|Canada Research Chairs Program; Canadian Institutes of Health Research; Terry Fox new investigator award; Canadian Institutes of Health Research new investigator award; Ontario Region Canadian Breast Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada through the Ontario Genomics Institute [OGI-055]; Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD) [115766]; Janssen; Merck KGaA (Darmstadt, Germany); MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome

Available from: 2019-01-07 Created: 2019-01-07 Last updated: 2019-01-07

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sunnerhagen, Maria
By organisation
ChemistryFaculty of Science & Engineering
In the same journal
Molecular Cell
Biochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 36 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf